Kirstein M - Search Results

1

Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study.

Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Baruchel S, Pratt C. Furman WL, et al. Among authors: kirstein m. J Clin Oncol. 2002 Mar 15;20(6):1617-24. doi: 10.1200/JCO.2002.20.6.1617. J Clin Oncol. 2002. PMID: 11896112 Clinical Trial.

2

A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.

Santana VM, Zamboni WC, Kirstein MN, Tan M, Liu T, Gajjar A, Houghton PJ, Stewart CF. Santana VM, et al. Among authors: kirstein mn. Clin Cancer Res. 2003 Feb;9(2):633-40. Clin Cancer Res. 2003. PMID: 12576429 Clinical Trial.

3

Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.

Stewart CF, Iacono LC, Chintagumpala M, Kellie SJ, Ashley D, Zamboni WC, Kirstein MN, Fouladi M, Seele LG, Wallace D, Houghton PJ, Gajjar A. Stewart CF, et al. Among authors: kirstein mn. J Clin Oncol. 2004 Aug 15;22(16):3357-65. doi: 10.1200/JCO.2004.10.103. J Clin Oncol. 2004. PMID: 15310781 Clinical Trial.

4

Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection.

Bai F, Kirstein MN, Hanna SK, Iacono LC, Johnston B, Stewart CF. Bai F, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Feb 5;784(2):225-32. doi: 10.1016/s1570-0232(02)00798-5. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 12505770

5

Topoisomerase I interactive agents.

Kirstein MN, Turner PK, Stewart CF. Kirstein MN, et al. Cancer Chemother Biol Response Modif. 2002;20:99-123. Cancer Chemother Biol Response Modif. 2002. PMID: 12703202 Review.

6

Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts.

Kirstein MN, Houghton PJ, Cheshire PJ, Richmond LB, Smith AK, Hanna SK, Stewart CF. Kirstein MN, et al. Clin Cancer Res. 2001 Feb;7(2):358-66. Clin Cancer Res. 2001. PMID: 11234891

7

Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.

Panetta JC, Kirstein MN, Gajjar A, Nair G, Fouladi M, Heideman RL, Wilkinson M, Stewart CF. Panetta JC, et al. Among authors: kirstein mn. Cancer Chemother Pharmacol. 2003 Dec;52(6):435-41. doi: 10.1007/s00280-003-0670-4. Epub 2003 Sep 16. Cancer Chemother Pharmacol. 2003. PMID: 13680158 Clinical Trial.

8

Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.

Middlemas DS, Stewart CF, Kirstein MN, Poquette C, Friedman HS, Houghton PJ, Brent TP. Middlemas DS, et al. Among authors: kirstein mn. Clin Cancer Res. 2000 Mar;6(3):998-1007. Clin Cancer Res. 2000. PMID: 10741727

9

Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.

Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Kirstein MN, Poquette CA, Tan M, Friedman HS, Brent TP. Houghton PJ, et al. Among authors: kirstein mn. Clin Cancer Res. 2000 Oct;6(10):4110-8. Clin Cancer Res. 2000. PMID: 11051264

10

A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas.

Panetta JC, Kirstein MN, Gajjar AJ, Nair G, Fouladi M, Stewart CF. Panetta JC, et al. Among authors: kirstein mn. Math Biosci. 2003 Nov;186(1):29-41. doi: 10.1016/j.mbs.2003.07.002. Math Biosci. 2003. PMID: 14527745

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

197 results

Search Page

Filters